BONE & BONE MATRIX BUILDERS: KEY FRONTIERS IN OSTEOPOROSIS MANAGEMENT

Osteoporosis remains a critical global health concern. While conventional therapies have predominantly focused on calcium and vitamin D supplementation alongside anti-resorptive agents, recent advances have emphasized the importance of enhancing not only mineral density but also the quality and functionality of the bone matrix. Particular focus is given to the utility of mineral transporters, such as calcium aspartate and calcium orotate, which exhibit superior bioavailability and enhanced cellular uptake compared to traditional calcium salts, including carbonate and citrate. These organo-mineral compounds facilitate targeted intracellular mineral delivery, stimulate osteoblastic activity, and contribute to matrix remodeling, resulting in promising outcomes that include increased bone mineral density and a reduction in fracture incidence. Emerging evidence suggests that such formulations support better absorption kinetics and minimize adverse systemic effects commonly associated with conventional supplementation. This review explored the mechanistic basis of these mineral transporters and their integration into contemporary osteoporosis management protocols. The evolving paradigm advocates for a shift towards bone health strategies that are not merely density-driven but matrix-conscious and bioavailability-optimized. Future studies should prioritize high-quality clinical trials to substantiate these promising therapeutic agents.